Heparin-induced thrombocytopenia (an overview)

International Journal of Clinical Practice

Volumn 61, Issue 1, 2007, Pages 130-137

  Daneschvar, H L ^a   Daw, Hamed ^b  

^a FAIRVIEW HOSPITAL   (United States)

^b LERNER RESEARCH INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ARGATROBAN; DANAPAROID; FONDAPARINUX; HEPARIN; HIRULOG; IMMUNOGLOBULIN; LEPIRUDIN; RECOMBINANT BLOOD CLOTTING FACTOR 7A; RECOMBINANT HIRUDIN; STREPTOKINASE; WARFARIN;

ALOPECIA; ANAPHYLAXIS; ANTICOAGULATION; ARTERY THROMBOSIS; BACKACHE; BLEEDING; CLINICAL PRACTICE; DEATH; DEEP VEIN THROMBOSIS; DIAGNOSTIC ACCURACY; DIFFERENTIAL DIAGNOSIS; DISEASE ASSOCIATION; DRUG EXPOSURE; DRUG INDUCED DISEASE; DRUG WITHDRAWAL; EOSINOPHILIA; ERYTHEMA; HEADACHE; HEART INFARCTION; HEPARINIZATION; HUMAN; HYPERCOAGULABILITY; HYPERKALEMIA; HYPOALDOSTERONISM; HYPOTENSION; IMMUNE RESPONSE; LABORATORY DIAGNOSIS; LIVER FUNCTION; NAUSEA; OSTEOPOROSIS; PAPULAR RASH; PRIAPISM; PRIORITY JOURNAL; REVIEW; SIDE EFFECT; SKIN NECROSIS; STROKE; THROMBOCYTOPENIA; THROMBOSIS; URTICARIA; VENOUS THROMBOEMBOLISM;

ANTICOAGULANTS; HEPARIN; HUMANS; INTENSIVE CARE; THROMBOCYTOPENIA;

EID: 33847034096     PISSN: 13685031     EISSN: 17421241     Source Type: Journal    
DOI: 10.1111/j.1742-1241.2006.00874.x     Document Type: Review

References (65)

1. Chong BH. Heparin-induced thrombocytopenia. Br J Haematol 1995; 89: 431-9.
2. Warkentin TE. Clinical presentation of heparin-induced thrombocytopenia. Semin Hematol 1998; 35: 9-16; discussion 35-6.
3. Francis JL, Palmer GJ, Moroose R, Drexler A. Comparison of bovine and porcine heparin in heparin antibody formation after cardiac surgery. Ann Thorac Surg 2003; 75: 17-22.
4. Sanson BJ, Lensing AW, Prins MH et al. Safety of low-molecular-weight heparin in pregnancy: a systematic review. Thromb Haemost 1999; 81: 668-72.
5. Warkentin TE, Levine MN, Hirsh J et al. Heparin-induced thrombocytopenia in patients treated with low-molecular-weight heparin or unfractionated heparin. N Engl J Med 1995; 332: 1330-5.
6. Kappa JR, Fisher CA, Berkowitz HD, Cottrell ED, Addonizio VP Jr. Heparin-induced platelet activation in sixteen surgical patients: diagnosis and management. J Vasc Surg 1987; 5: 101-9.
7. Warkentin TE, Kelton JG. A 14-year study of heparin-induced thrombocytopenia. Am J Med 1996; 101: 502-7.
8. Daneschvar HL, Daw H. An elderly woman with leg swelling and pain. Cleve Clin J Med 2005; 72: 353-8.
9. Weismann RE, Tobin RW. Arterial embolism occurring during systemic heparin therapy. AMA Arch Surg 1958; 76: 219-25; discussion 225-7.
10. Bell WR, Royall RM. Heparin-associated thrombocytopenia: a comparison of three heparin in preparation. N Engl J Med 1980; 303: 902-7.
11. Alving BM, Shulman NR, Bell WR, Evatt BL, Tack KM. In vitro studies of heparin-associated thrombocytopenia. Thromb Res 1977; 11: 827-34.
12. Warkentin TE, Roberts RS, Hirsh J, Kelton JG. An improved definition of immune heparin-induced thrombocytopenia in postoperative orthopedic patients. Arch Intern Med 2003; 163: 2518-24.
13. Warkentin TE. Heparin-induced thrombocytopenia: pathogenesis and management. Br J Haematol 2003; 121: 535-55.
14. Cipolle RJ, Rodvold KA, Seifert R, Clarens R, Ramirez-Lassepas M. Heparin-associated thrombocytopenia: a prospective evaluation of 211 patients. Ther Drug Monit 1983; 5: 205-11.
15. Arepally GM, Mayer IM. Antibodies from patients with heparin-induced thrombocytopenia stimulate monocytic cells to express tissue factor and secrete interleukin-8. Blood 2001; 98: 1252-4.
16. Walenga JM, Jeske WP, Fasanella AR, Wood JJ, Ahmad S, Bakhos M. Laboratory diagnosis of heparin-induced thrombocytopenia. Clin Appl Thromb Hemost 1999; 5 (Suppl. 1): S21-7.
17. Walenga JM, Jeske WP, Fasanella AR, Wood JJ, Bakhos M. Laboratory tests for the diagnosis of heparin-induced thrombocytopenia. Semin Thromb Hemost 1999; 25 (Suppl. 1): 43-9.
18. Warkentin TE, Kelton JG. Temporal aspects of heparin-induced thrombocytopenia. N Engl J Med 2001; 344: 1286-92.
19. Lubenow N, Kempf R, Eichner A, Eichler P, Carlsson LE, Greinacher A. Heparin-induced thrombocytopenia: temporal pattern of thrombocytopenia in relation to initial use or reexposure to heparin. Chest 2002; 122: 37-42.
20. Warkentin TE, Greinacher A. Heparin-induced thrombocytopenia: recognition, treatment, and prevention: the Seventh ACCP Conference on and Thrombolytic Therapy. Chest 2004; 126: 311S-37S.
21. Nand S, Wong W, Yuen B, Yetter A, Schmulbach E, Gross Fisher S. Heparin-induced thrombocytopenia with thrombosis: incidence, analysis of risk factors, and clinical outcomes in 108 consecutive patients treated at a single institution. Am J Hematol 1997; 56: 12-6.
22. Ginsberg JS, Brill-Edwards P, Burrows RF et al. Venous thrombosis during pregnancy: leg and trimester of presentation. Thromb Haemost 1992; 67: 519-20.
23. Arthur CK, Grant SJ, Murray WK, Isbister JP, Stiel JN, Lauer CS. Heparin-associated acute adrenal insufficiency. Aust N Z J Med 1985; 15: 454-5.
24. Dahlberg PJ, Goellner MH, Pehling GB. Adrenal insufficiency secondary to adrenal hemorrhage. Two case reports and a review of cases confirmed by computed tomography. Arch Intern Med 1990; 150: 905-9.
25. Srinivasan AF, Rice L, Bartholomew JR et al. Warfarin-induced skin necrosis and venous limb gangrene in the setting of heparin-induced thrombocytopenia. Arch Intern Med 2004; 164: 66-70.
26. Warkentin TE, Elavathil LJ, Hayward CP, Johnston MA, Russett JI, Kelton JG. The pathogenesis of venous limb gangrene associated with heparin-induced thrombocytopenia. Ann Intern Med 1997; 127: 804-12.
27. Boshkov LK, Warkentin TE, Hayward CP, Andrew M, Kelton JG. Heparin-induced thrombocytopenia and thrombosis: clinical and laboratory studies. Br J Haematol 1993; 84: 322-8.
28. Ganzer D, Gutezeit A, Mayer G, Greinacher A, Eichler P. Prevention of thromboembolism as a cause of thromboembolic complications. A study of the incidence of heparin-induced thrombocytopenia type II. Z Orthop Ihre Grenzgeb 1997; 135: 543-9.
29. Warkentin TE, Sheppard JA, Horsewood P, Simpson PJ, Moore JC, Kelton JG. Impact of the patient population on the risk for heparin-induced thrombocytopenia. Blood 2000; 96: 1703-8.
30. Bauer TL, Arepally G, Konkle BA et al. Prevalence of heparin-associated antibodies without thrombosis in patients undergoing cardiopulmonary bypass surgery. Circulation 1997; 95: 1242-6.
31. Jackson MR, Gillespie DL, Chang AS, Longenecker EG, Peat RA, Alving BM. The incidence of heparin-induced antibodies in patients undergoing vascular surgery: a prospective study. J Vasc Surg 1998; 28: 439-44; discussion 445.
32. Visentin GP, Ford SE, Scott JP, Aster RH. Antibodies from patients with heparin-induced thrombocytopenia/thrombosis are specific for platelet factor 4 complexed with heparin or bound to endothelial cells. J Clin Invest 1994; 93: 81-8.
33. Pouplard C, Amiral J, Borg JY, Laporte-Simitsidis S, Delahousse B, Gruel Y. Decision analysis for use of platelet aggregation test, carbon 14-serotonin release assay, and heparin-platelet factor 4 enzyme-linked immunosorbent assay for diagnosis of heparin-induced thrombocytopenia. Am J Clin Pathol 1999; 111: 700-6.
34. Eichler P, Budde U, Haas S et al. First workshop for detection of heparin-induced antibodies: validation of the heparin-induced platelet-activation test (HIPA) in comparison with a PF4/heparin ELISA. Thromb Haemost 1999; 81: 625-9.
35. Greinacher A, Michels I, Kiefel V, Mueller-Eckhardt C. A rapid and sensitive test for diagnosing heparin-associated thrombocytopenia. Thromb Haemost 1991; 66: 734-6.
36. Harenberg J, Huhle G, Giese C et al. Determination of serotonin release from platelets by enzyme immunoassay in the diagnosis of heparin-induced thrombocytopenia. Br J Haematol 2000; 109: 182-6.
37. Sheridan D, Carter C, Kelton JG. A diagnostic test for heparin-induced thrombocytopenia. Blood 1986; 67: 27-30.
38. Kelton JG, Sheridan D, Santos A et al. Heparin-induced thrombocytopenia: laboratory studies. Blood 1988; 72: 925-30.
39. Warkentin TE, Hayward CP, Boshkov LK et al. Sera from patients with heparin-induced thrombocytopenia generate platelet-derived microparticles with procoagulant activity: an explanation for the thrombotic complications of heparin-induced thrombocytopenia. Blood 1994; 84: 3691-9.
40. Tardy-Poncet B, Tardy B, Reynaud J et al. Efficacy and safety of danaparoid sodium (ORG 10172) in critically ill patients with heparin-associated thrombocytopenia. Chest 1999; 115: 1616-20.
41. Greinacher A, Eichler P, Lubenow N, Kwasny H, Luz M. Heparin-induced thrombocytopenia with thromboembolic complications: meta-analysis of 2 prospective trials to assess the value of parenteral treatment with lepirudin and its therapeutic aPTT range. Blood 2000; 96: 846-51.
42. Cohen JI, Cooper MR, Greenberg CS. Streptokinase therapy of pulmonary emboli with heparin-associated thrombocytopenia. Arch Intern Med 1985; 145: 1725-6.
43. Fiessinger JN, Aiach M, Roncato M, Debure C, Gaux JC. Critical ischemia during heparin-induced thrombocytopenia. Treatment by intra-arterial streptokinase. Thromb Res 1984; 33: 235-8.
44. Ranze O, Ranze P, Magnani HN, Greinacher A. Heparin-induced thrombocytopenia in paediatric patients - a review of the literature and a new case treated with danaparoid sodium. Eur J Pediatr 1999; 158 (Suppl. 3): S130-3.
45. Ranze O, Rakow A, Ranze P, Eichler P, Greinacher A, Fusch C. Low-dose danaparoid sodium catheter flushes in an intensive care infant suffering from heparin-induced thrombocytopenia. Pediatr Crit Care Med 2001; 2: 175-7.
46. Macchi L, Sarfati R, Guicheteau M et al. Thromboembolic prophylaxis with danaparoid (Orgaran) in a high-thrombosis-risk pregnant woman with a history of heparin-induced thrombocytopenia (HIT) and Widal's disease. Clin Appl Thromb Hemost 2000; 6: 187-9.
47. Lewis BE, Walenga JM, Wallis DE. Anticoagulation with Novastan (argatroban) in patients with heparin-induced thrombocytopenia and heparin-induced thrombocytopenia and thrombosis syndrome. Semin Thromb Hemost 1997; 23: 197-202.
48. Walenga JM, Bick RL. Heparin-induced thrombocytopenia, paradoxical thromboembolism, and other side effects of heparin therapy. Med Clin North Am 1998; 82: 635-58.
49. Nand S, Robinson JA. Plasmapheresis in the management of heparin-associated thrombocytopenia with thrombosis. Am J Hematol 1988; 28: 204-6.
50. Greinacher A, Volpel H, Janssens U et al. Recombinant hirudin (lepirudin) provides safe and effective anticoagulation in patients with heparin-induced thrombocytopenia: a prospective study. Circulation 1999; 99: 73-80.
51. Swan SK, Hursting MJ. The pharmacokinetics and pharmacodynamics of argatroban: effects of age, gender, and hepatic or renal dysfunction. Pharmacotherapy 2000; 20: 318-29.
52. Swan SK, St Peter JV, Lambrecht LJ, Hursting MJ. Comparison of anticoagulant effects and safety of argatroban and heparin in healthy subjects. Pharmacotherapy 2000; 20: 756-70.
53. Matsuo T, Kario K, Chikahira Y, Nakao K, Yamada T. Treatment of heparin-induced thrombocytopenia by use of argatroban, a synthetic thrombin inhibitor. Br J Haematol 1992; 82: 627-9.
54. Henny CP, Ten Cate H, Ten Cate JW et al. Use of a new heparinoid as anticoagulant during acute haemodialysis of patients with bleeding complications. Lancet 1983; 1: 890-3.
55. Chong BH, Berndt MC. Heparin-induced thrombocytopenia. Blut 1989; 58: 53-7.
56. Salmi L, Leroy-Matheron C, LeBesnerais P, Rosanval O, Duvaldestin P, Gouault-Heilmann M. Extracorporeal circulation with danaparoid sodium for valve replacement in thrombocytopenia induced by type II heparin. Ann Fr Anesth Reanim 2001; 20: 799-802.
57. Fernandes P, Mayer R, MacDonald JL, Cleland AG, Hay-McKay C. Use of danaparoid sodium (Orgaran) as an alternative to heparin sodium during cardiopulmonary bypass: a clinical evaluation of six cases. Perfusion 2000; 15: 531-9.
58. Kanagasabay RR, Unsworth-White MJ, Robinson G et al. Cardiopulmonary bypass with danaparoid sodium and ancrod in heparin-induced thrombocytopenia. Ann Thorac Surg 1998; 66: 567-9.
59. Walenga JM, Bakhos M, Messmore HL et al. Comparison of recombinant hirudin and heparin as an anticoagulant in a cardiopulmonary bypass model. Blood Coagul Fibrinolysis 1991; 2: 105-11.
60. Riess FC, Bleese N, Kormann J et al. Recombinant hirudin is a heparin alternative in cardiac surgery. J Cardiothorac Vasc Anesth 1997; 11: 538-9.
61. Campbell KR, Mahaffey KW, Lewis BE et al. Bivalirudin in patients with heparin-induced thrombocytopenia undergoing percutaneous coronary intervention. J Invasive Cardiol 2000; 12 (Suppl. F): 14F-19F.
62. Topol EJ, Bonan R, Jewitt D et al. Use of a direct antithrombin, hirulog, in place of heparin during coronary angioplasty. Circulation 1993; 87: 1622-9.
63. Fondaparinux (Arixtra), a new anticoagulant Med Lett Drugs Ther 2002; 44: 43-4.
64. Vanholder RC, Camez AA, Veys NM et al. Recombinant hirudin: a specific thrombin inhibiting anticoagulant for hemodialysis. Kidney Int 1994; 45: 1754-9.
65. Fischer KG, van de Loo A, Bohler J. Recombinant hirudin (lepirudin) as anticoagulant in intensive care patients treated with continuous hemodialysis. Kidney Int Suppl 1999; 72: S46-50.